**Table S2.** Antitumor response rates in patients with a pre-existing PNS (cohort 1).

|  |  |  |
| --- | --- | --- |
| Cohort 1: patients with a pre-existing PNS (n = 16 patients) | Exacerbation of a pre-existing PNS during anti-PD1 or PD-L1 immunotherapy? | p-value# |
| No (n=8) | Yes (n=8) |
| Objective response\*, n pts (%)Complete responsePartial response | 4 (50)04 | 5 (63)23 | p=0.614 |
| No objective response \*, n pts (%)Stable diseaseProgressive disease | 4 (50)22 | 3 (37)12 |

\* The best overall response to anti-PD1 or PD-L1 immunotherapy. Antitumor responses were assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (version 1.1), as modified for use in clinical trials with immune checkpoint inhibitors.

# Pearson's chi-squared test